Innovation for safety and optimal results 1
Long-lasting results for sustained effectiveness
SAFETY
A UNIQUE AND SAFE COMPOSITION
Ellansé is available in two options: S and M with results lasting for 18 months and 24 months respectively,* distinguished only by the initial polymer chain length of the PCL.
From its launch in 2009, Ellansé’s excellent safety profile has been continuously reported, not only in clinical trials and vigilance surveys but also by clinical experts in daily practice. 3
S M ELLANSÉ 18 MONTHS * ELLANSÉ 24 MONTHS *
PCL
In a review of adverse events from launch to August 2022, the adverse event rate was 0.0462% - or 1 event in 2,165 syringes. 4
ADVERSE EVENT RATE BY TYPE: 4
PCL is biodegradable and bioresorbable, naturally hydrolysed by the body into CO 2 and H 2 O. 5
0.0207%
0.0032%
* Treatment effects have variable duration dependant on the variant used, practitioner injection technique, patient lifestyle and metabolic rate.
NODULES / LUMPS
HARDNESS / INDURATION
CMC
0.0008%
0.0121%
ELLANSÉ LONGEVITY OPTIONS The PCL microspheres’ unique biodegradation pattern maintains a longer effective lifetime than other dermal fillers, which start to degrade from day one.
CMC is a widely-used component classified as generally recognised as safe (GRAS). 5
INFECTION
SWELLING
S
M
0.0031%
0.0010%
CMC Effect:
INFLAMMATION
BRUISING / HAEMATOMA
PCL Microsphere Effect:
4 weeks
6 8
12 weeks
18 months 24 months
6 ELLANSÉ PRACTITIONER GUIDE
7 ELLANSÉ PRACTITIONER GUIDE
Made with FlippingBook interactive PDF creator